80/100B160.420
USD
-2.88
(-1.76%)
Pre Open
Last updated: · Delayed 15 min
Fair value128.72Plus+25%103Price 160.42634
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Novartis market capWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
Novartis's market cap is 302.97B USD: 1,888,623,686 shares outstanding at today's price of 160.42.
- Today
- 302.97B
- Average, 5 years
- 218.64B
- Low, 5 years
- 154.51B
- High, 5 years
- 322.58B
Market cap = price × shares outstanding = 160.42 × 1.89B = 302.97B
Each day's closing price times the shares outstanding in the last 10-Q or 10-K filed by then (the quarter's basic share count, adjusted for splits); from the latest count on, the shares outstanding now.
Market cap by year and by quarter
| Fiscal year | Period ending | Market cap |
|---|---|---|
| Today | 302.97B | |
| FY2025 | 31 Dec 2025 | 267.32B |
| FY2024 | 31 Dec 2024 | 196.40B |
| FY2023 | 31 Dec 2023 | 209.69B |
| FY2022 | 31 Dec 2022 | 187.25B |
| FY2021 | 31 Dec 2021 | 185.62B |
| FY2020 | 31 Dec 2020 | 203.48B |
| FY2019 | 31 Dec 2019 | 205.26B |
| FY2018 | 31 Dec 2018 | 166.50B |
| FY2017 | 31 Dec 2017 | 164.79B |
| FY2016 | 31 Dec 2016 | 144.94B |
| FY2015 | 31 Dec 2015 | 172.98B |
| FY2014 | 31 Dec 2014 | 188.06B |
| FY2013 | 31 Dec 2013 | 164.16B |
| FY2012 | 31 Dec 2012 | 128.06B |
| FY2011 | 31 Dec 2011 | 113.93B |
| FY2010 | 31 Dec 2010 | 112.75B |
| FY2009 | 31 Dec 2009 | 103.28B |
| FY2008 | 31 Dec 2008 | 94.31B |
| FY2007 | 31 Dec 2007 | 105.31B |
| FY2006 | 31 Dec 2006 | 112.71B |
| FY2005 | 31 Dec 2005 | 102.43B |
| FY2004 | 31 Dec 2004 | 99.59B |
| FY2003 | 31 Dec 2003 | 91.37B |
| FY2002 | 31 Dec 2002 | 77.30B |
| FY2001 | 31 Dec 2001 | 78.54B |
| FY2000 | 31 Dec 2000 | 98.55B |
| FY1999 | 31 Dec 1999 | 78.56B |
| FY1998 | 31 Dec 1998 | 109.68B |
| Quarter | Period ending | Market cap |
|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 270.31B |
| Q2 FY2026 | 30 Jun 2026 | 298.55B |
| Q1 FY2026 | 31 Mar 2026 | 291.60B |
| Q4 FY2025 | 31 Dec 2025 | 263.75B |
| Q3 FY2025 | 29 Sept 2025 | 239.02B |
| Q2 FY2025 | 30 Jun 2025 | 235.73B |
| Q1 FY2025 | 31 Mar 2025 | 219.39B |
| Q4 FY2024 | 31 Dec 2024 | 193.35B |
| Q3 FY2024 | 30 Sept 2024 | 231.42B |
| Q2 FY2024 | 30 Jun 2024 | 216.60B |
| Q1 FY2024 | 31 Mar 2024 | 195.96B |
| Q4 FY2023 | 31 Dec 2023 | 206.99B |
| Q3 FY2023 | 30 Sept 2023 | 198.76B |
| Q2 FY2023 | 30 Jun 2023 | 198.91B |
| Q1 FY2023 | 31 Mar 2023 | 183.70B |
| Q4 FY2022 | 31 Dec 2022 | 183.29B |
| Q3 FY2022 | 30 Sept 2022 | 155.87B |
| Q2 FY2022 | 30 Jun 2022 | 175.82B |
| Q1 FY2022 | 31 Mar 2022 | 184.76B |
| Q4 FY2021 | 31 Dec 2021 | 185.16B |
| Q3 FY2021 | 30 Sept 2021 | 173.12B |
| Q2 FY2021 | 30 Jun 2021 | 193.66B |
| Q1 FY2021 | 31 Mar 2021 | 182.16B |
| Q4 FY2020 | 31 Dec 2020 | 202.40B |
| Q3 FY2020 | 30 Sept 2020 | 188.03B |
| Q2 FY2020 | 30 Jun 2020 | 189.19B |
| Q1 FY2020 | 31 Mar 2020 | 177.50B |
| Q4 FY2019 | 31 Dec 2019 | 202.94B |
| Q3 FY2019 | 30 Sept 2019 | 186.83B |
| Q2 FY2019 | 30 Jun 2019 | 200.79B |
| Q1 FY2019 | 31 Mar 2019 | 185.63B |
| Q4 FY2018 | 31 Dec 2018 | 165.83B |
| Q3 FY2018 | 30 Sept 2018 | 167.21B |
| Q2 FY2018 | 30 Jun 2018 | 147.07B |
| Q1 FY2018 | 31 Mar 2018 | 157.33B |
| Q4 FY2017 | 31 Dec 2017 | 163.12B |
| Q3 FY2017 | 30 Sept 2017 | 167.72B |
| Q2 FY2017 | 30 Jun 2017 | 164.40B |
| Q1 FY2017 | 31 Mar 2017 | 147.40B |
| Q4 FY2016 | 31 Dec 2016 | 144.73B |
| Q3 FY2016 | 30 Sept 2016 | 157.16B |
| Q2 FY2016 | 30 Jun 2016 | 164.36B |
| Q1 FY2016 | 31 Mar 2016 | 144.19B |
| Q4 FY2015 | 31 Dec 2015 | 171.70B |
| Q3 FY2015 | 30 Sept 2015 | 184.97B |
| Q2 FY2015 | 30 Jun 2015 | 198.95B |
| Q1 FY2015 | 31 Mar 2015 | 198.74B |
| Q4 FY2014 | 31 Dec 2014 | 186.67B |
| Q3 FY2014 | 30 Sept 2014 | 190.73B |
| Q2 FY2014 | 30 Jun 2014 | 184.50B |
| Q1 FY2014 | 31 Mar 2014 | 173.56B |
| Q4 FY2013 | 31 Dec 2013 | 163.55B |
| Q3 FY2013 | 30 Sept 2013 | 156.73B |
| Q2 FY2013 | 30 Jun 2013 | 145.44B |
| Q1 FY2013 | 31 Mar 2013 | 145.12B |
| Q4 FY2012 | 31 Dec 2012 | 128.16B |
| Q3 FY2012 | 30 Sept 2012 | 125.01B |
| Q2 FY2012 | 30 Jun 2012 | 113.23B |
| Q1 FY2012 | 31 Mar 2012 | 111.96B |
| Q4 FY2011 | 31 Dec 2011 | 115.08B |
| Q3 FY2011 | 30 Sept 2011 | 113.10B |
| Q2 FY2011 | 30 Jun 2011 | 122.66B |
| Q1 FY2011 | 31 Mar 2011 | 104.14B |
| Q4 FY2010 | 31 Dec 2010 | 112.85B |
| Q3 FY2010 | 30 Sept 2010 | 110.40B |
| Q2 FY2010 | 30 Jun 2010 | 92.49B |
| Q1 FY2010 | 31 Mar 2010 | 103.15B |
| Q4 FY2009 | 31 Dec 2009 | 103.29B |
| Q3 FY2009 | 30 Sept 2009 | 95.60B |
| Q2 FY2009 | 30 Jun 2009 | 77.25B |
| Q1 FY2009 | 31 Mar 2009 | 71.72B |
| Q4 FY2008 | 31 Dec 2008 | 94.20B |
| Q3 FY2008 | 30 Sept 2008 | 100.10B |
| Q2 FY2008 | 30 Jun 2008 | 104.39B |
| Q1 FY2008 | 31 Mar 2008 | 97.19B |
| Q4 FY2007 | 31 Dec 2007 | 103.46B |
| Q3 FY2007 | 30 Sept 2007 | 106.73B |
| Q2 FY2007 | 30 Jun 2007 | 109.71B |
| Q1 FY2007 | 31 Mar 2007 | 107.20B |
| Q4 FY2006 | 31 Dec 2006 | 112.82B |
| Q3 FY2006 | 30 Sept 2006 | 114.77B |
| Q2 FY2006 | 30 Jun 2006 | 105.83B |
| Q1 FY2006 | 31 Mar 2006 | 108.52B |
| Q4 FY2005 | 31 Dec 2005 | 102.55B |
| Q3 FY2005 | 30 Sept 2005 | 100.02B |
| Q2 FY2005 | 30 Jun 2005 | 92.46B |
| Q1 FY2005 | 31 Mar 2005 | 91.28B |
| Q4 FY2004 | 31 Dec 2004 | 103.19B |
| Q3 FY2004 | 30 Sept 2004 | 95.31B |
| Q2 FY2004 | 30 Jun 2004 | 91.47B |
| Q1 FY2004 | 31 Mar 2004 | 87.84B |
| Q4 FY2003 | 31 Dec 2003 | 95.13B |
| Q3 FY2003 | 30 Sept 2003 | 80.54B |
| Q2 FY2003 | 30 Jun 2003 | 82.34B |
| Q1 FY2003 | 31 Mar 2003 | 76.68B |
| Q4 FY2002 | 31 Dec 2002 | 76.13B |
| Q3 FY2002 | 30 Sept 2002 | 84.03B |
| Q2 FY2002 | 30 Jun 2002 | 91.84B |
| Q1 FY2002 | 31 Mar 2002 | 84.08B |
| Q4 FY2001 | 31 Dec 2001 | 77.94B |
| Q3 FY2001 | 30 Sept 2001 | 83.24B |
| Q2 FY2001 | 30 Jun 2001 | 78.26B |
| Q1 FY2001 | 31 Mar 2001 | 85.26B |
| Q4 FY2000 | 31 Dec 2000 | 99.39B |
| Q3 FY2000 | 30 Sept 2000 | 83.91B |
| Q2 FY2000 | 30 Jun 2000 | 85.46B |
| Q1 FY2000 | 31 Mar 2000 | 71.73B |
See also:P/E ratio,P/S ratio,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios
Common questions about Novartis's market cap
Source: Financial Modeling Prep